Novartis achieves breakthrough in Sjögren’s syndrome with successful Phase III trials
TL;DR Summary
Novartis announced positive results from its Phase III trials of ianalumab, demonstrating significant improvement in disease activity for Sjögren’s disease, potentially making it the first targeted treatment for this autoimmune disorder. The trials showed the drug was well tolerated and could soon be submitted for regulatory approval.
- Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease Novartis
- Novartis Gets Boost as Autoimmune Drug Suceeds in Key Trials Bloomberg.com
- Novartis plans Sjögren’s disease filings as antibody passes two Phase 3 studies Endpoints News
- Novartis scores double phase 3 win in Sjögren's syndrome, succeeding where rivals failed Fierce Biotech
- Novartis posts encouraging results for Sjögren’s syndrome therapy SWI swissinfo.ch
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
8 min
vs 9 min read
Condensed
97%
1,606 → 47 words
Want the full story? Read the original article
Read on Novartis